At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 37 enrolled
Drug / intervention
Bimatoprost SR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
In Brief
A Phase 3 clinical trial evaluating Bimatoprost SR and LUMIGAN for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 37 participants across 6 sites.
Detailed Summary
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJun 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedFeb 26, 2020
Enrollment StartJun 11, 2020
Primary CompletionMay 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.4 years ago
Interventions
Bimatoprost SRdrug
Consists of 1 Bimatoprost SR administration in the study eye.
LUMIGANdrug
Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.